Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26597111)

Published in Appl Health Econ Health Policy on February 01, 2016

Authors

Ataru Igarashi1, Rei Goto2,3, Kiyomi Suwa4, Reiko Yoshikawa4, Alexandra J Ward5, Jörgen Moller6

Author Affiliations

1: Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo Bunkyo, Tokyo, 113-0033, Japan. atarui1@mac.com.
2: Hakubi Center of Advanced Research, Kyoto University, Yoshida-ushinomiyacho, Sakyo, Kyoto, 6068501, Japan.
3: Graduate School of Economics, Kyoto University, Yoshida-honmachi, Sakyo, Kyoto, 6068501, Japan.
4: Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan.
5: Evidera, 430 Bedford Street, Suite 300, Lexington, MA, 02420, USA.
6: Evidera, Metro Building, 6th Floor, 1 Butterwick, Hammersmith, London, W6 8DL, UK.

Articles cited by this

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 10.54

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA (2006) 10.31

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax (2005) 7.39

Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax (2008) 4.79

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation (2010) 4.50

COPD in Japan: the Nippon COPD Epidemiology study. Respirology (2004) 2.81

Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest (2010) 2.75

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ (2010) 2.57

Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol (2014) 2.23

Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther (2007) 2.12

Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Making (2006) 2.09

Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke (2003) 2.05

The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis (1963) 1.83

Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan: a comparative risk assessment. PLoS Med (2012) 1.70

Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV. Addict Behav (1999) 1.68

Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med (2006) 1.59

Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med (2004) 1.40

Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction (2012) 1.32

Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. Cost Eff Resour Alloc (2008) 1.13

Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up study. Addiction (2009) 1.12

Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokers. Clin Ther (2014) 0.88

Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics (2009) 0.84

A catalogue of EQ-5D utility weights for chronic diseases among noninstitutionalized community residents in Korea. Value Health (2010) 0.83

Long-term prognosis of patients with acute myocardial infarction in the era of acute revascularization (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry). Int J Cardiol (2011) 0.83

Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventions. Pharmacoeconomics (2013) 0.80

Web-based survey on smoking cessation behaviors of current and former smokers in Japan. Curr Med Res Opin (2014) 0.78

Medical care for chronic-phase stroke in Japan. Neurol Med Chir (Tokyo) (2012) 0.77

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics (2011) 0.77